carnitine has been researched along with Brain Disorders in 30 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In systemic carnitine deficiency, an early phase of nonketotic hypoglycemia and liver dysfunction may precede a late phase of encephalopathy and myopathy." | 7.66 | Nonketotic hypoglycemia: an early indicator of systemic carnitine deficiency. ( Borum, PR; Diamond, MP; Mrak, RE; Najjar, J; Richardson, D; Slonim, AE, 1983) |
| "L-Carnitine is an essential cofactor in transfer of long-chain fatty acids across the inner mitochondrial membrane." | 6.36 | Carnitine metabolism and deficiency syndromes. ( Engel, AG; Rebouche, CJ, 1983) |
| "Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children." | 5.51 | Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019) |
| "Neurological injury because of transient cerebral ischemia is a potential complication of cardiovascular surgery." | 5.33 | Neuroprotective effects of L-carnitine and vitamin E alone or in combination against ischemia-reperfusion injury in rats. ( Aral, E; Aybek, H; Baltalarli, A; Baycu, C; Bir, LS; Coskun, E; Enli, Y; Oguz, EO; Onem, G; Ozcan, AV; Sacar, M, 2006) |
| "The association of macrocephaly, dystonia, and bilateral temporal arachnoid cysts, shown either by computed tomography or magnetic resonance imaging, seems to be diagnostic of glutaric aciduria type 1." | 5.29 | Macrocephaly, dystonia, and bilateral temporal arachnoid cysts: glutaric aciduria type 1. ( Casas, C; Fernández, MA; Martínez-Lage, JF; Poza, M; Puche, A; Rodriguez Costa, T, 1994) |
| "To evaluate the effects of L-carnitine on impaired brain function in patients with liver cirrhosis." | 3.96 | Impaired brain function improved by L-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy. ( Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kubota, Y; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Nakanishi, K; Noda, T; Okada, M; Osawa, L; Sekiguchi, S; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wan, W; Yamashita, K; Yasui, Y, 2020) |
| "We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
| "A 24-years-old woman with epilepsy treated with valproic acid developed disorientation, acalculia, perseveration, slow responsiveness and loss of memory." | 3.70 | [A case report of valproate encephalopathy]. ( Hirata, K; Katayama, S; Miyamoto, M; Miyamoto, T, 1999) |
| "In systemic carnitine deficiency, an early phase of nonketotic hypoglycemia and liver dysfunction may precede a late phase of encephalopathy and myopathy." | 3.66 | Nonketotic hypoglycemia: an early indicator of systemic carnitine deficiency. ( Borum, PR; Diamond, MP; Mrak, RE; Najjar, J; Richardson, D; Slonim, AE, 1983) |
| "L-Carnitine is an essential cofactor in transfer of long-chain fatty acids across the inner mitochondrial membrane." | 2.36 | Carnitine metabolism and deficiency syndromes. ( Engel, AG; Rebouche, CJ, 1983) |
| "A 9-month-old patient was admitted with encephalopathy and acute loss of acquired motor skills during the course of COVID-19 disease." | 1.62 | COVID-19 triggered encephalopathic crisis in a patient with glutaric aciduria type 1. ( Ahmadzada, S; Aktuglu-Zeybek, C; Kiykim, E; Yalcinkaya, C; Zubarioglu, T, 2021) |
| "Levocarnitine is the treatment of choice in valproic acid toxicity-related hyperammonaemia." | 1.62 | Managing valproic acid toxicity-related hyperammonaemia: an unpredicted course. ( Edquist, C; O'Rourke, N; Pagali, S, 2021) |
| "Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children." | 1.51 | Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019) |
| "Neurodevelopmental delay and encephalopathy are complications of both HIV and GA1." | 1.48 | Favourable outcome in a child with symptomatic diagnosis of Glutaric aciduria type 1 despite vertical HIV infection and minor head trauma. ( Ackermann, C; Cotton, MF; Dobbels, EFM; Laughton, B; Springer, PE; Thomas, A, 2018) |
| "To examine the clinical features and risk factors of secondary carnitine deficiency due to long-term use of pivalate-conjugated antibiotics (PCAs)." | 1.43 | Clinical Features of Carnitine Deficiency Secondary to Pivalate-Conjugated Antibiotic Therapy. ( Fukuda, S; Hasegawa, Y; Kobayashi, H; Purevsuren, J; Takahashi, T; Yamada, K; Yamaguchi, S, 2016) |
| "We report the first case of acute encephalopathy induced by vaccination in an infant with methylmalonic aciduria cblA in China." | 1.42 | [Acute encephalopathy induced by vaccination in an infant with methylmalonic aciduria cblA]. ( Ding, Y; Li, X; Liu, Y; Song, J; Wang, H; Wang, Q; Wu, T; Yang, Y; Zhang, Y, 2015) |
| " The vast knowledge on the carnitine/acylcarnitine translocase is essential both as a progress in basic science and as instrument to foresee therapeutic or toxic effects of xenobiotics and drugs." | 1.42 | Mitochondrial carnitine/acylcarnitine translocase: insights in structure/ function relationships. Basis for drug therapy and side effects prediction. ( Console, L; Giangregorio, N; Indiveri, C; Tonazzi, A, 2015) |
| "Carnitine supplement was administrated in two patients, which resulted in resolution of symptoms and normalized ammonium levels." | 1.40 | Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease). ( Larsen, EP; Ostergaard, JR, 2014) |
| "Carnitine is an essential co-factor in fatty acid metabolism." | 1.35 | Hyperammonemic encephalopathy caused by carnitine deficiency. ( Limketkai, BN; Zucker, SD, 2008) |
| "Neurological injury because of transient cerebral ischemia is a potential complication of cardiovascular surgery." | 1.33 | Neuroprotective effects of L-carnitine and vitamin E alone or in combination against ischemia-reperfusion injury in rats. ( Aral, E; Aybek, H; Baltalarli, A; Baycu, C; Bir, LS; Coskun, E; Enli, Y; Oguz, EO; Onem, G; Ozcan, AV; Sacar, M, 2006) |
| "The association of macrocephaly, dystonia, and bilateral temporal arachnoid cysts, shown either by computed tomography or magnetic resonance imaging, seems to be diagnostic of glutaric aciduria type 1." | 1.29 | Macrocephaly, dystonia, and bilateral temporal arachnoid cysts: glutaric aciduria type 1. ( Casas, C; Fernández, MA; Martínez-Lage, JF; Poza, M; Puche, A; Rodriguez Costa, T, 1994) |
| "Of the nine patients with encephalopathy, eight showed improvement in their mental status." | 1.27 | Plasma carnitine deficiency. Clinical observations in 51 pediatric patients. ( Curry, CJ; Hogue, R; Hutchinson, HT; Shug, A; Szabo-Aczel, S; Winter, SC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.00) | 18.7374 |
| 1990's | 4 (13.33) | 18.2507 |
| 2000's | 5 (16.67) | 29.6817 |
| 2010's | 12 (40.00) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zubarioglu, T | 1 |
| Ahmadzada, S | 1 |
| Yalcinkaya, C | 1 |
| Kiykim, E | 1 |
| Aktuglu-Zeybek, C | 1 |
| Nakanishi, H | 1 |
| Hayakawa, Y | 1 |
| Kubota, Y | 1 |
| Kurosaki, M | 1 |
| Osawa, L | 1 |
| Inada, K | 1 |
| Kirino, S | 1 |
| Yamashita, K | 1 |
| Sekiguchi, S | 1 |
| Okada, M | 1 |
| Wan, W | 1 |
| Higuchi, M | 1 |
| Takaura, K | 1 |
| Maeyashiki, C | 1 |
| Kaneko, S | 1 |
| Tamaki, N | 1 |
| Yasui, Y | 1 |
| Noda, T | 1 |
| Nakanishi, K | 1 |
| Tsuchiya, K | 1 |
| Itakura, J | 1 |
| Takahashi, Y | 1 |
| Izumi, N | 1 |
| Pagali, S | 1 |
| Edquist, C | 1 |
| O'Rourke, N | 1 |
| Thomas, A | 1 |
| Dobbels, EFM | 1 |
| Springer, PE | 1 |
| Ackermann, C | 1 |
| Cotton, MF | 1 |
| Laughton, B | 1 |
| Camilleri, L | 1 |
| Fukui, KO | 1 |
| Kubota, M | 1 |
| Terashima, H | 1 |
| Ishiguro, A | 1 |
| Kashii, H | 1 |
| Boruczkowski, D | 1 |
| Pujal, JM | 1 |
| Zdolińska-Malinowska, I | 1 |
| Larsen, EP | 1 |
| Ostergaard, JR | 1 |
| Villalba Martínez, G | 1 |
| Fernández-Candil, JL | 1 |
| Vivanco-Hidalgo, RM | 1 |
| Pacreu Terradas, S | 1 |
| León Jorba, A | 1 |
| Arroyo Pérez, R | 1 |
| Liu, Y | 1 |
| Wu, T | 1 |
| Wang, H | 1 |
| Ding, Y | 1 |
| Song, J | 1 |
| Li, X | 1 |
| Zhang, Y | 1 |
| Wang, Q | 1 |
| Yang, Y | 1 |
| Tonazzi, A | 1 |
| Giangregorio, N | 1 |
| Console, L | 1 |
| Indiveri, C | 1 |
| Al-sharefi, A | 1 |
| Bilous, R | 1 |
| Kobayashi, H | 1 |
| Fukuda, S | 1 |
| Yamada, K | 1 |
| Hasegawa, Y | 1 |
| Takahashi, T | 1 |
| Purevsuren, J | 1 |
| Yamaguchi, S | 1 |
| Ozsoy, SY | 1 |
| Ozsoy, B | 1 |
| Ozyildiz, Z | 1 |
| Aytekin, I | 1 |
| Gokmen-Ozel, H | 1 |
| MacDonald, A | 1 |
| Daly, A | 1 |
| Ashmore, C | 1 |
| Preece, MA | 1 |
| Hendriksz, C | 1 |
| Vijay, S | 1 |
| Chakrapani, A | 1 |
| Spiekerkoetter, U | 1 |
| Huener, G | 1 |
| Baykal, T | 1 |
| Demirkol, M | 1 |
| Duran, M | 1 |
| Wanders, R | 1 |
| Nezu, J | 1 |
| Mayatepek, E | 1 |
| Bischof, F | 1 |
| Nägele, T | 1 |
| Wanders, RJ | 1 |
| Trefz, FK | 1 |
| Melms, A | 1 |
| Onem, G | 1 |
| Aral, E | 1 |
| Enli, Y | 1 |
| Oguz, EO | 1 |
| Coskun, E | 1 |
| Aybek, H | 1 |
| Ozcan, AV | 1 |
| Sacar, M | 1 |
| Bir, LS | 1 |
| Baltalarli, A | 1 |
| Baycu, C | 1 |
| Merinero, B | 1 |
| Pérez-Cerdá, C | 1 |
| Ruiz Sala, P | 1 |
| Ferrer, I | 1 |
| García, MJ | 1 |
| Martínez Pardo, M | 1 |
| Belanger-Quintana, A | 1 |
| de la Mota, JL | 1 |
| Martin-Hernández, E | 1 |
| Vianey-Saban, C | 1 |
| Bischoff, C | 1 |
| Gregersen, N | 1 |
| Ugarte, M | 1 |
| Limketkai, BN | 1 |
| Zucker, SD | 1 |
| Rebouche, CJ | 1 |
| Engel, AG | 1 |
| Kim, CS | 1 |
| Dorgan, DR | 1 |
| Roe, CR | 1 |
| Slonim, AE | 1 |
| Borum, PR | 1 |
| Mrak, RE | 1 |
| Najjar, J | 1 |
| Richardson, D | 1 |
| Diamond, MP | 1 |
| Di Donato, S | 1 |
| Rimoldi, M | 1 |
| Cornelio, F | 1 |
| Bottacchi, E | 1 |
| Giunta, A | 1 |
| Averbuch-Heller, L | 1 |
| Ben-Hur, T | 1 |
| Reches, A | 1 |
| Martínez-Lage, JF | 1 |
| Casas, C | 1 |
| Fernández, MA | 1 |
| Puche, A | 1 |
| Rodriguez Costa, T | 1 |
| Poza, M | 1 |
| Miyamoto, T | 1 |
| Miyamoto, M | 1 |
| Hirata, K | 1 |
| Katayama, S | 1 |
| Murakami, K | 1 |
| Sugimoto, T | 2 |
| Nishida, N | 2 |
| Kobayashi, Y | 1 |
| Kuhara, T | 1 |
| Matsumoto, I | 1 |
| Winter, SC | 1 |
| Szabo-Aczel, S | 1 |
| Curry, CJ | 1 |
| Hutchinson, HT | 1 |
| Hogue, R | 1 |
| Shug, A | 1 |
| Woo, M | 1 |
| Takeuchi, T | 1 |
| Yasuhara, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
3 reviews available for carnitine and Brain Disorders
| Article | Year |
|---|---|
Lesson of the month 1: Sodium valproate-induced encephalopathy.
Topics: Aged; Ammonia; Anticonvulsants; Brain Diseases; Carnitine; Consciousness Disorders; Epilepsy; Humans | 2018 |
Autologous cord blood in children with cerebral palsy: a review.
Topics: 3-Hydroxybutyric Acid; Amino Acids; Animals; Brain Diseases; Brain Injuries; Carnitine; Cerebral Pal | 2019 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
Carnitine metabolism and deficiency syndromes.
Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre | 1983 |
27 other studies available for carnitine and Brain Disorders
| Article | Year |
|---|---|
COVID-19 triggered encephalopathic crisis in a patient with glutaric aciduria type 1.
Topics: Amino Acid Metabolism, Inborn Errors; Brain; Brain Diseases; Brain Diseases, Metabolic; Carnitine; C | 2021 |
Impaired brain function improved by L-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy.
Topics: Aged; Brain Diseases; Carnitine; Female; Humans; Liver Cirrhosis; Male; Prognosis; Retrospective Stu | 2020 |
Managing valproic acid toxicity-related hyperammonaemia: an unpredicted course.
Topics: Adult; Brain Diseases; Carnitine; Drug Overdose; Female; Humans; Hyperammonemia; Valproic Acid; Youn | 2021 |
Favourable outcome in a child with symptomatic diagnosis of Glutaric aciduria type 1 despite vertical HIV infection and minor head trauma.
Topics: Amino Acid Metabolism, Inborn Errors; Atrophy; Brain; Brain Diseases; Brain Diseases, Metabolic; Car | 2018 |
Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study.
Topics: Brain Diseases; Carnitine; Case-Control Studies; Child, Preschool; Diagnosis, Differential; Disease | 2019 |
Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
Topics: Adolescent; Anticonvulsants; Brain Diseases; Carnitine; Drug Therapy, Combination; Female; Humans; H | 2014 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
[Acute encephalopathy induced by vaccination in an infant with methylmalonic aciduria cblA].
Topics: Amino Acid Metabolism, Inborn Errors; Brain Diseases; Carnitine; Diet, Protein-Restricted; Hepatitis | 2015 |
Mitochondrial carnitine/acylcarnitine translocase: insights in structure/ function relationships. Basis for drug therapy and side effects prediction.
Topics: Amino Acid Sequence; Animals; Anti-Bacterial Agents; Bacterial Infections; Brain Diseases; Cardiovas | 2015 |
Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency.
Topics: Adult; Antimanic Agents; Brain Diseases; Cardiomyopathies; Carnitine; Female; Humans; Hyperammonemia | 2015 |
Clinical Features of Carnitine Deficiency Secondary to Pivalate-Conjugated Antibiotic Therapy.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Brain Diseases; Carnitine; Child; Child, Preschool; Female | 2016 |
Protective effect of L-carnitine on experimental lead toxicity in rats: a clinical, histopathological and immunohistochemical study.
Topics: Animals; Blood Cells; Brain Diseases; Carnitine; Chemical and Drug Induced Liver Injury; Enzymes; He | 2011 |
Dietary practices in glutaric aciduria type 1 over 16 years.
Topics: Adolescent; Adult; Age Factors; Amino Acid Metabolism, Inborn Errors; Biomarkers; Brain Diseases; Br | 2012 |
Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2.
Topics: Adult; Brain Diseases; Carnitine; Carrier Proteins; Child, Preschool; Fibroblasts; Homozygote; Human | 2003 |
3-hydroxy-3-methylglutaryl-CoA lyase deficiency in an adult with leukoencephalopathy.
Topics: Adult; Brain Diseases; Carnitine; Female; Fibroblasts; Glutarates; Humans; Hypoglycemia; Leukocytes; | 2004 |
Neuroprotective effects of L-carnitine and vitamin E alone or in combination against ischemia-reperfusion injury in rats.
Topics: Animals; Antioxidants; Brain; Brain Diseases; Brain Ischemia; Carnitine; Drug Therapy, Combination; | 2006 |
Persistent increase of plasma butyryl/isobutyrylcarnitine concentrations as marker of SCAD defect and ethylmalonic encephalopathy.
Topics: Brain Diseases; Butyryl-CoA Dehydrogenase; Carnitine; Humans; Malonates; Mitochondrial Proteins; Ner | 2006 |
Hyperammonemic encephalopathy caused by carnitine deficiency.
Topics: Adult; Ammonia; Brain Diseases; Carnitine; Fatty Acids; Female; Gastric Bypass; Humans; Lipid Metabo | 2008 |
L-carnitine: therapeutic strategy for metabolic encephalopathy.
Topics: Animals; Biological Transport, Active; Brain Diseases; Caprylates; Carnitine; Choroid Plexus; In Vit | 1984 |
Nonketotic hypoglycemia: an early indicator of systemic carnitine deficiency.
Topics: Brain Diseases; Carnitine; Child; Child, Preschool; Female; Humans; Hypoglycemia; Liver; Male; Muscl | 1983 |
Evidence for autosomal recessive inheritance in systemic carnitine deficiency.
Topics: Brain Diseases; Carnitine; Child, Preschool; Female; Humans; Muscular Diseases | 1982 |
Valproate encephalopathy and hypocarnitinaemia in diabetic patients.
Topics: Adolescent; Adult; Brain Diseases; Carnitine; Diabetes Mellitus, Type 1; Electroencephalography; Epi | 1994 |
Macrocephaly, dystonia, and bilateral temporal arachnoid cysts: glutaric aciduria type 1.
Topics: Arachnoid Cysts; Brain; Brain Diseases; Carnitine; Dystonia; Female; gamma-Aminobutyric Acid; Glutar | 1994 |
[A case report of valproate encephalopathy].
Topics: Adult; Ammonia; Anticonvulsants; Biomarkers; Brain; Brain Diseases; Carnitine; Epilepsy; Female; Hum | 1999 |
Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy.
Topics: Brain Diseases; Carnitine; Cerebral Palsy; Child; Chronic Disease; Female; Gas Chromatography-Mass S | 1992 |
Plasma carnitine deficiency. Clinical observations in 51 pediatric patients.
Topics: Adolescent; Brain Diseases; Cardiomyopathies; Carnitine; Child; Child, Preschool; Failure to Thrive; | 1987 |
[Significance of serum carnitine in acute encephalopathy].
Topics: Acute Disease; Adolescent; Brain Diseases; Carnitine; Child; Child, Preschool; Diagnosis, Differenti | 1985 |